• Ongoing phase 3 study with up to 450 patients, including RRMM patients who are refractory to lenalidomide
  • Direct comparison with pomalidomide in patients treated with IMiDs and PIs, and who have become refractory to their last line of therapy
  • The study is designed to demonstrate benefit in comparison with pomalidomide
  • Started in Q2 2017 with last patient in expected in Q1 2020